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http://dx.doi.org/10.1016/j.ccell.2015.09.007SUMMARYAcentral question in glioblastomamultiforme (GBM) research is the identity of the tumor-initiating cell, and its
contribution to the malignant phenotype and genomic state. We examine the potential of adult lineage-
restricted progenitors to induce fully penetrant GBM using CNS progenitor-specific inducible Cre mice to
mutate Nf1, Trp53, and Pten. We identify two phenotypically and molecularly distinct GBM subtypes gov-
erned by identical driver mutations. We demonstrate that the two subtypes arise from functionally indepen-
dent pools of adult CNS progenitors. Despite histologic identity as GBM, these tumor types are separable
based on the lineage of the tumor-initiating cell. These studies point to the cell of origin as a major determi-
nant of GBM subtype diversity.INTRODUCTION
Glioblastoma multiforme (GBM) remains one of the most lethal
forms of adult human cancer, with a median survival of approx-
imately 1 year from time of diagnosis (Stupp et al., 2005; Wen
and Kesari, 2008). Its invasive and rapidly progressive nature
has prompted numerous studies on the origins of these highly
malignant tumors. Traditionally, the concept that cancer can
spontaneously develop from any or most somatic cells was
widely accepted and GBM was thought to be derived from as-
trocytes (Sanai et al., 2005). Given the need for accumulation of
multiple mutations, the unlimited self-renewal potential of stem
cells would more easily allow such events during the lifetime of
an individual, making them more accessible targets for malig-
nant transformation (Chen et al., 2012b; Reya et al., 2001).
Accordingly, adult stem cells exhibit tumor-initiating potential
in animal models of leukemia, breast, lung, colon, and otherSignificance
The cell of origin, including the role of adult lineage-restricted p
Emerging human genomic data have been used to stratify GBM
contribute to GBM using cell type-specific mouse models prov
progression. Our findings showing different adult CNS progen
driver of tumor subtype has important implications for functio
relevant target pathways.
Corgan cancers (Alcantara Llaguno et al., 2009; Sell, 2010; Vis-
vader, 2011). In the brain, direct or indirect targeting of the tu-
mor suppressors Nf1, Trp53, and Pten in adult mouse neural
stem cells induces high-grade gliomas that faithfully pheno-
copy the human malignancy (Alcantara Llaguno et al., 2009;
Chen et al., 2012a; Jacques et al., 2010). In the experimental
setting, the transformation of more mature neural cells to
form tumors has been reported. However, how such a manip-
ulation could relate to the physiological setting of gradually
accumulating mutations is less clear (Friedmann-Morvinski
et al., 2012).
The role of adult lineage-restricted progenitors in solid tumor
etiology is not well characterized. Unlike multipotent stem cells,
most progenitors have limited self-renewal and are fated to
differentiate into postmitotic cells that present impediments to
transformation (Huntly et al., 2004; Lillien, 1998). In hematologic
malignancies, it has been shown that leukemias can ariserogenitors in glioblastoma, is an area of ongoing controversy.
into subgroups. Identification of the CNS cell lineages that
ides unique insight into mechanisms of tumor initiation and
itors as GBM-initiating cells and the cell of origin as a major
nal subclassification of GBM and identification of subtype
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from stem cells, myeloid, and lymphoid progenitors (Krivtsov
et al., 2006). Some oncogenes, such as MOZ-TIF2 and MLL-
AF9, but not BCR-ABL, transform committed hematopoietic
progenitors and confer properties of stem cells, like enhanced
self-renewal (Huntly et al., 2004). Other studies indicate that
initiating mutations in stem cells can create leukemia of
committed progenitor phenotype, indicating that progenitors
can be important cellular incubators of leukemia (Cozzio
et al., 2003). How these scenarios play out in the case of gli-
omas is not known.
In mature rodent brain, new neurons are continually produced
in the adult subventricular zone (SVZ) of the lateral ventricles and
the subgranular zone (SGZ) of the dentate gyrus (Alvarez-Buylla
and Lim, 2004; Zhao et al., 2008). In the SVZ and SGZ, neural
stem cells (NSCs) are relatively quiescent, glial fibrillary acidic
protein (Gfap)-expressing cells that exhibit lifelong self-renewal
potential and generate neural progenitor cells (NPCs) whose
fate and terminal differentiation are rapidly achieved. NPCs are
transit-amplifying cells that typically undergo several rounds of
cell division before forming new neurons that migrate either
from the SVZ through the rostral migratory stream (RMS) and
into the olfactory bulb (OB) or locally within the dentate gyrus
(Doetsch et al., 1999; Zhao et al., 2008). Oligodendrocyte pro-
genitor cells (OPCs), on the other hand, are broadly arrayed in
the adult brain, where they constitute the largest pool of dividing
cells. These cells are responsible for generating myelin-forming
oligodendrocytes in the developing and mature CNS, and are
the source of myelin-forming cells following demyelinating le-
sions (Nishiyama et al., 2009).
To specifically target discrete adult progenitor populations in
the brain, we used Cre transgenic mice that drive recombination
in different adult CNS cell types. Specific regulatory elements of
the rat Nestin gene have been harnessed to specify transgene
expression to adult neural stem cells of the SVZ and SGZ (Alcan-
tara Llaguno et al., 2009; Chen et al., 2009, 2012a); regulatory
elements of the mouse Ascl1 (Achaete-scute family bHLH
transcription factor 1; also known asMash1) gene direct recom-
bination specifically in the SVZ and SGZ adult committed neural
progenitor lineage and adult OPCs (Kim et al., 2007, 2008); and
those of the mouse Cspg4 (chondroitin sulfate proteoglycan 4)
gene, which encodes for NG2, are specific for OPCs in the adult
mouse brain (Zhu et al., 2011). In this study, we investigate theFigure 1. Tumor Suppressor Inactivation in Adult Lineage-Restricted C
(A) Schematic of Ascl1-creERTM transgene (top). Immunohistochemical staining
together with the neural stem cell–specific marker Gfap, neural stem/progenitor m
neuronal marker NeuN, OPCmarker Olig2, andmature oligodendrocyte marker A
(B) Kaplan-Meier survival curves of AscNP and AscNPPmice induced with tamoxi
p = 0.0782.
(C) Kaplan-Meier survival curves of AscNPmice inducedwith a single dose (SD) or
p = 0.8044.
(D) Representative H&E brain sections of AscNP and AscNPP mutant (mut) br
features: indistinct tumor borders, with tumor cells (T) diffusely infiltrating into adja
mitotic figures (asterisk; h) are shown. Scale bars, a and b represent 1 mm; c–h
(E) Bar graph showing percentage of AscNP and AscNPP tumors classified as W
(F) Expression of high-grade gliomamarkers such as Ki67, Gfap, Nestin, and Olig2
Scale bar represents 200 mm.
(G) Western blot analysis of Nf1, p53, and Pten in AscNP, NG2NPP, and NesNP
(H) Expression of mature differentiation markers (Gfap for astrocytes, NeuN for n
b-galactosidase positive (cre+) tumor cells in AscNP tumors with R26-stop-lacZ
See also Figure S1.
Crole of adult neural and oligodendrocyte progenitors in the devel-
opment of GBM.
RESULTS
We previously identified adult SVZ neural stem cells as an effi-
cient source of gliomas in mouse models caused by inactivation
of Nf1, Trp53, and Pten, three of the most commonly mutated
genes in human GBM (Alcantara Llaguno et al., 2009; Cancer
Genome Atlas Research Network, 2008). To specifically target
adult lineage-restricted CNS progenitors to the exclusion of
stem cells, we turned to a transgenic mouse line that expresses
tamoxifen-inducible Cre recombinase under the control of Ascl1
regulatory elements (Kim et al., 2007, 2008; Mich et al., 2014).
Using the Ascl1-creERTM;R26-stop-lacZ reporter, X-gal staining
of tamoxifen-treated mouse brains verified specific recombina-
tion in the SVZ-RMS-OB and the SGZ at 2 weeks post-induction
(Figure S1A). LacZ+ cells were also found in white matter and
subcortical gray matter regions, including corpus callosum,
hypothalamus and thalamic regions, where OPCs and their
progeny are located. Immunostaining of Ascl1-creERTM;R26-
stop-YFP reporter brains showed colocalization of the YFP
signal with markers for adult neural and oligodendrocyte line-
ages (Figures 1A and S1B). YFP co-localized with neural stem
and progenitor markers Sox2 and Nestin but not the stem cell-
specific marker Gfap in the SVZ and SGZ (Alvarez-Buylla and
Lim, 2004; Zhao et al., 2008). YFP also co-stained with the imma-
ture neuronal marker doublecortin (Dcx) and themature neuronal
marker NeuN in the RMS-OB and the dentate gyrus, as well
as the OPC marker Olig2 and mature oligodendrocyte marker
APC in OPC regions such as the thalamus. These data confirm
the expression of the Ascl1-creERTM transgene in a subset
of adult CNS progenitors and their derivatives, but not in stem
cells.
Adult Lineage-Restricted CNS Progenitors Produce
Glioma
To determine whether tumor suppressor deletion in adult
committed progenitors also efficiently generates malignant
gliomas, we bred Ascl1-creERTM mice to incorporate condi-
tional and/or null alleles of Nf1, Trp53, and Pten to yield
the following genotypes: Ascl1-creERTM;Nf1flox/flox;Trp53flox/floxNS Progenitors, but Not Stem Cells, Initiates GBM
of Ascl1-creERTM;R26-stop-YFP reporter adult mouse brain sections for YFP
arkers Sox2 and Nestin, immature neuronal marker doublecortin (Dcx), mature
PC. Arrowheadsmark YFP/marker co-localization. Scale bar represents 20 mm.
fen at 4 weeks of age. Median survival: AscNP, 40 weeks; AscNPP, 36.7 weeks;
double dose (DD) of tamoxifen. Median survival: SD, 39weeks; DD, 33.5 weeks
ains compared to controls (con; a–f). High-grade gliomas with characteristic
cent normal (NT) regions (e), pseudopalisading necrosis (N; g) and presence of
represent 100 mm.
HO grade III or IV gliomas (n = 16 AscNP, n = 9 AscNPP mice).
, as well as progenitor markers Sox2 and Pdgfra in AscNP and AscNPP tumors.
P tumors. Tubulin is used as a loading control.
eurons, and myelin basic protein or Mbp for oligodendrocytes) in a subset of
reporter. Scale bar represents 100 mm.
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Figure 2. Increased Proliferation and Accelerated Differentiation Precede Tumor Formation
(A) AscNP R26-stop-lacZ and control reporter mice were administered tamoxifen at 4 weeks of age and analyzed 4 months later by X-gal staining. CC, corpus
callosum. Scale bar represents 200 mm.
(B) Proliferation (based on Ki67 staining) and expression of various markers (Gfap, Nestin, Dcx, Olig2) in the SVZ and OB of AscNP and control brains. Scale bars
represent 200 mm.
(C) Immunohistochemistry with BrdU and progenitor markers following short term BrdU pulses. Scale bar represents 20 mm.
(D) Quantification of Ki67+ cells in SVZ (n = 4 mutants, 4 controls; p < 0.05).
(E) Quantification of Dcx+ cells in OB (n = 4 mutants, 4 controls; p = 0.0001).
(F) Quantification of BrdU+ cells in thalamus (n = 3 mutants, 3 controls; p < 0.0001).
(G) Quantification of Olig2+ cells in thalamus (n = 3 mutants, 3 controls; p < 0.01). All statistical analyses used Student’s t test. All error bars denote mean ± SEM.
See also Figure S2.or Ascl1-creERTM;Nf1flox/flox;Trp53flox/ (AscNP), and Ascl1-
creERTM;Nf1flox/flox;Trp53flox/flox;Ptenflox/+ (AscNPP). Adult mu-
tants and controls were induced with tamoxifen or vehicle at
4 weeks of age. AscNP and AscNPP mice showed accelerated
morbidity (Figure 1B). Furthermore, one or two tamoxifen doses
had similar tumor kinetics and median survival in AscNP mice,
suggesting saturation of recombination efficiency (Figure 1C).
Analysis of symptomatic AscNP and AscNPP mice demon-
strated malignant gliomas (Figures 1D and 1E). H&E staining
showed the classical features of diffusely infiltrating high-grade
gliomas (Figure 1D), with indistinct tumor borders (Figure 1De),
pseudopalisading necrosis (Figure 1Dg), and prominent mitoses
(Figure 1Dh). Control mice (Figures 1Db, Dd, and Df) did not
develop tumors. AscNP and AscNPP tumors were classified as
grade III (anaplastic astrocytoma) or grade IV (glioblastoma mul-
tiforme) based on the World Health Organization (WHO) classifi-
cation system (Louis et al., 2007; Figure 1E). The gliomas were
immunoreactive for the classical markers Ki67, Gfap, Nestin,432 Cancer Cell 28, 429–440, October 12, 2015 ª2015 Elsevier Inc.and Olig2, as well as progenitor markers Sox2 and platelet-
derived growth factor receptor a (Pdgfra; Figure 1F). Cre-medi-
ated tumor suppressor deletion in AscNP mice was verified by
genotyping (Figure S1C), and western blot analysis, showing
absence of the Nf1 protein and accumulation of mutant p53 pro-
tein (Figure 1G). These data demonstrate that Nf1, Trp53, and
Pten tumor suppressor inactivation in adult lineage-restricted
progenitor cells is sufficient to induce malignant glioma.
In vivo, AscNP tumor cells undergomulti-lineagedifferentiation
(Figure 1H). b-galactosidase-positive tumor cells were immuno-
reactive formarkers of astrocytes (Gfap; S100b; data not shown),
neurons (NeuN), and oligodendrocytes (myelin basic protein,
Mbp). Freshly dissociated AscNP tumors grown in growth fac-
tor-supplemented, serum-free media produced tumorspheres,
self-renewandundergomulti-lineagedifferentiationwhen shifted
to serum-containing media (Figures S1D and S1E). Thus, adult
progenitor-driven gliomas exhibit stem cell-like properties
including self-renewal and multipotency when tested in vitro.
Figure 3. AscNP and AscNPP Mutants Form Two Identifiable GBM Subtypes
(A) Left: representative H&E staining images of AscNP and AscNPP brain sections showing a subgroup of gliomas in the dorsal brain and another subgroup found
in ventral/basal region. Black boxesmark tumor regions. Scale bar represents 1mm. Right: bar graph showing the percentage of gliomas in the dorsal and ventral
brain regions that were identified in AscNP (n = 13) and AscNPP (n = 7) mutants.
(B) H&E staining images of mutant brains showing tumor borders, at three different magnifications. Scale bars represent 200 mM.
(C) Bar graph showing the percentage of tumors that exhibit diffuse versus well-defined tumor borders in dorsal (n = 12) and ventral (n = 8) tumors found in AscNP
and AscNPP mice.
(D) Immunohistochemistry of GBM markers in glioma subtypes found in AscNP and AscNPP mice. Scale bar represents 200 mM.
(E) Bar graph showing the percentage of dorsal (n = 12) and ventral (n = 8) tumors that shows high versus low Gfap expression.
(F) Schematic showing the general features of type 1 versus type 2 gliomas. Type 1 gliomas are mostly diffuse tumors commonly found in the dorsal
brain and exhibit high Gfap expression. Type 2 tumors are generally found in the ventral brain, show well-defined tumor borders, and exhibit low Gfap
expression.
(G) Bar graph showing the percentage of type 1 and 2 tumors in AscNP (n = 13) and AscNPP (n = 7) mouse models.
(H) Quantification of Ki67+ cells per high power field (20x magnification; n = 4 type 1 tumors, n = 4 type 2 tumors; p < 0.05).
(I) Quantification of Cleaved Caspase-3+ cells per high power field (20x magnification; n = 3 type 1 tumors, n = 5 type 2 tumors; p < 0.005). All statistical analyses
used Student’s t test. All error bars denote mean ± SEM.
See also Figure S3.Early Proliferation and Migration Defects in Mutant
Adult CNS Progenitors
To gain insight into the early events in glioma formation, we
analyzed pre-symptomatic AscNP mice. At 1 month post-
tamoxifen induction, no abnormal histology was detected (data
not shown), but at 4 months post-induction, we observed evi-Cdence of abnormal proliferation, differentiation, and migration
(Figure 2). X-gal staining of AscNP mutants showed enhanced
staining of recombined lacZ+ cells in the adult neural and oligo-
dendrocyte progenitor regions compared to age-matched con-
trols (Figure 2A). In the SVZ, AscNP mice showed enhanced
Ki67 and Nestin staining, as well as increased short-term BrdUancer Cell 28, 429–440, October 12, 2015 ª2015 Elsevier Inc. 433
Figure 4. Differential Growth of Transplanted Type 1 and Type 2
GBM Cells
(A) Schematic of transplantation experiments. Type 1 and type 2 tumors from
symptomatic AscNP mice were cultured in serum-free media with growth
factors and 23 105 tumor cells were subsequently transplanted into the dorsal
striatum (arrow) of adult immunodeficient mice.
(B) Kaplan-Meier survival curve of nude mice transplanted with type 1 (n = 6)
compared with type 2 tumor cells (n = 6); p < 0.01. Two independent lines for
each tumor subtype were tested. Figure shows a representative survival curve
for the independent lines used for each type.
(C) H&E staining of tumors from type 1 versus type 2 transplanted mice, and
bar graph showing percentage of transplanted tumors with diffuse or well-
defined tumor borders (n = 6 tumors for each type analyzed). Scale bars
represent 200 mm.
(D) Immunohistochemical staining using glioma markers. Scale bar represents
200 mm. Insets show higher magnification images of Gfap staining (scale bar
represents 20 mm).
(E) Mbp staining showing association with myelin fibers and fiber bundles in
tumor regions of type 1 versus type 2 transplanted mice. Right sub-panels
show higher magnification images of a type 1 tumor in the cortex (top) and
striatum (bottom). Scale bars represent 200 mm.
(F) Immunofluoresence staining forOlig2 (tumor cells) andMbpwithin the tumor
bulk of type 1 and type 2 transplanted gliomas. Scale bars represent 200 mm.(bromodeoxyuridine) incorporation (Figures 2B and 2C) and pro-
liferation index (Figure 2D). In contrast, the AscNP SVZ appeared
depleted of doublecortin (Dcx), with reduced Dcx+ newborn neu-
rons, but with increased number of Dcx+ cells in their final desti-
nation, the olfactory bulb (Figures 2B and 2E). We observed no434 Cancer Cell 28, 429–440, October 12, 2015 ª2015 Elsevier Inc.difference in apoptosis (Figure S2). These data reveal early
migratory and differentiation abnormalities in AscNP adult neural
progenitors.
AscNP OPCs also showed increased lacZ staining (Figure 2A)
and proliferation in short-term BrdU pulse-chases (Figures 2C
and 2F), as well as increased abundance of the OPC marker
Olig2 (Figures 2B, 2C, and 2G). Thus, both mutant adult neural
and oligodendrocytic progenitors exhibit enhanced proliferation,
differentiation, and migration alterations in advance of obvious
tumor formation.
AscNP and NPP Mice Develop Two GBM Variants
Overall, AscNP and AscNPP tumors displayed the classic histo-
pathologic hallmarks of diffuse, infiltrating gliomas, primarily
localized to the dorsal brain (telencephalon: cerebral cortex, hip-
pocampus, and caudate putamen; Figure 3A), and similar to the
majority of gliomas derived from the neural stem cell-specific
Nestin-creERT2 mutant mice (Alcantara Llaguno et al., 2009).
Detailed scrutiny, however, revealed a subset of tumors that
generally located to the ventral brain (diencephalon: thalamus
and hypothalamus, and brainstem: midbrain, pons, andmedulla;
Figure 3A) and tended to exhibit better-defined tumor borders
(Figures 3B and 3C). Compared to the more prevalent gliomas
identified in these and previous studies (Alcantara Llaguno
et al., 2009; Kwon et al., 2008; Zhu et al., 2005), the variant
GBM subset uniformly showed reduced immunoreactivity for
Gfap and Nestin coupled with enhanced Olig2 and Pdgfra
expression (Figures 3D and 3E). Immunoreactivity to other line-
age markers was similar for both tumor types (Figure S3A).
When dissociated and grown in serum-free, growth factor-sup-
plementedmedia, both GBM types displayed similar cell viability
(Figure S3B). Hereafter, we refer to the predominant, Gfaphigh
tumors as type 1 gliomas and the less frequent, Gfaplow variant
tumors as type 2 gliomas (Figure 3F).
Type 1 tumors are predominant in AscNPP mice while AscNP
mice develop both tumor types equally (Figure 3G). One possible
explanation may be that the presence of the Pten mutation in
AscNPP elicits faster development of the more infiltrative and
aggressive type 1 tumors, thus masking the development of
type 2 variant GBMs. Quantification of marker+ cells in tumor
brain sections show increased proliferation (Ki67+) and
decreased apoptosis (Cleaved Caspase 3+) in type 1 compared
to type 2 tumors (Figures 3H and 3I). These features are consis-
tent with two GBM subtypes that exhibit morphologic and
phenotypic differences.
Type 1 and 2 Gliomas Exhibit Characteristic Behavior
In Vivo
We tested whether type 1 and type 2 glioma differences reflect
intrinsic tumor cell properties or, alternatively, are influenced
bymicroenvironment (anatomic location).We transplanted equal
numbers of early passage AscNP type 1 and type 2 tumor cells
from two independent lines into the dorsal striatum (a common
type 1 site) of immunodeficient mice (Figure 4A). We found that
type 1 tumors confer significantly shorter median survival
compared to type 2 tumors, reflective of their more aggressive
nature (37 versus 126 days post-transplantation; Figure 4B)
and developed into correspondingly infiltrative, Gfaphigh-ex-
pressing gliomas (Figures 4C and 4D). On the other hand, the
Figure 5. Distinguishable Molecular Signa-
tures for Type 1 and Type 2 Gliomas
(A) Heatmap of 2700 differentially expressed genes
(DEGs) between AscNP tumors (n = 8) and controls
(n = 8) and the result of unsupervised hierarchical
clustering analysis.
(B) Locally linear embedding (LLE) dimension
reduction analysis depicting the DEGs projected in
3-dimensional space and showing separated
groups of dorsal and ventral tissue controls as well
as type 1 and type 2 gliomas (outlier removed).
(C) Heatmap of DEGs by direct comparison of
AscNP type 2 tumors with type 1 tumors.
(D) Gene ontology analysis of DEGs between type
1 and 2 tumors.
(E) Unsupervised hierarchical cluster analysis of
gene expression profiles of type 1 and 2 gliomas in
comparison with different adult murine CNS cell
types (derived from Cahoy et al., 2008).
See also Tables S1–S3.transplanted type 2 cells adhered to their original properties,
including relatively lower Gfap and Nestin, and higher Olig2
and Pdgfra staining (Figures 4C and 4D). Transplanted type 1 tu-
mor cells were also found extensively intercalated between
Mbp+ myelin fibers, consistent with its infiltrative nature (Figures
4E and 4F). Thus, type 1 and type 2 tumors behave cell
autonomously, conserving their unique histological characteris-
tics and intrinsically distinct growth behavior irrespective of
microenvironment.
Molecular Differences in Adult CNS Progenitor-Driven
Tumors
We next examined the gene expression profiles of AscNP pri-
mary gliomas and control tissue from dorsal (cortex and stria-
tum) or ventral (hypothalamus and hindbrain) brain regions of
age-matched controls by microarray. Unsupervised hierarchi-
cal clustering analysis demonstrated clear delineation between
tumor and control samples (Figure 5A). Dimension reduction
analysis using the locally linear embedding (LLE) method pro-
jected the 2,700 differentially expressed genes between tu-
mors and controls (Figure 5A; Table S1) into three-dimensional
space and showed clustering of the type 1 tumors separate
from type 2 tumors, as well as the dorsal and ventral control
groups (Figure 5B). Direct comparison between the clustered
type 1 and type 2 tumors showed clear separation, with differ-
entially expressed genes involved in transcriptional regulation
and neuronal development (Figures 5C and 5D; Tables S2
and S3).Cancer Cell 28, 429–440We next compared the transcriptional
profiles of AscNP tumors with different
CNS cell populations using murine brain
cell type-specific profiles defined by the
Barres group (Cahoy et al., 2008). Unsu-
pervised hierarchical clustering was
applied to the gene expression profiles
of AscNP type 1 and type 2 gliomas and
control samples, as well as OPCs, differ-
entiated oligodendrocytes, myelinating
oligodendrocytes (myelin OLs), astro-
cytes, and neurons. Clustering analysis best aligned type 2 tu-
mors with OPCs whereas type 1 gliomas had relatively greater
relatedness to astrocytes (Figure 5E). Taken together, these
data show that type 1 and 2 gliomas are molecularly distinct
and give strength to the hypothesis that they arise from different
cells of origin, reflecting the two different progenitor lineages tar-
geted by the Ascl1-creERTM transgene.
Type 2 Gliomas Are Adult OPC-Derived
To directly test the hypothesis that type 2 tumors are derived
from adult OPCs, we used an OPC-specific NG2-creERTM trans-
gene (Zhu et al., 2011). Immunohistochemical analysis verified
OPC specificity, including co-expression of the TdTomato re-
porter with the OPC marker Pdgfra and mature oligodendrocyte
marker APC, but not with NeuN, microglia marker Iba1, or Gfap
(Figure 6A).
NG2-creERTM with tumor suppressor conditional back-
ground (NG2-creERTM;Nf1flox/flox;Trp53flox/flox;Ptenflox/+ or NG2-
creERTM;Nf1flox/+;Trp53flox/flox;Ptenflox/+; NG2NPP), and tamox-
ifen-induced at 4–8 weeks of age, had a median survival of
21.1 weeks (Figure 6B), and developed WHO grade III or IV gli-
omas (Figures 6C–6E). NG2NPP tumors showed histologic and
molecular similarity to the type 2 AscNP and AscNPP tumors
(Figures 6D–6H), including the presence of pseudopalisading ne-
crosis (Figure 6Ea), with low Gfap and Nestin, but high Pdgfra
and Olig2 immunoreactivity (Figures 6F and S4A). As observed
for the type 2 AscNP andAscNPP tumors,more NG2NPP tumors
had better defined tumor borders compared to the more diffuse, October 12, 2015 ª2015 Elsevier Inc. 435
Figure 6. Adult Oligodendrocyte Progenitors Are the Source of Type 2 GBM
(A) NG2-creERTM transgene schematic (top). Immunohistochemical staining of NG2-creERTM;R26-stop-TdTomato reporter together with OPC marker Pdgfra,
mature oligodendrocyte marker APC, neuronal marker NeuN, microglial marker Iba1 and astrocytic marker Gfap in OPC regions such as the thalamus (area
denoted by white box in whole brain image). Arrowheads indicate co-localization of TdTomato with indicated marker. Scale bars for whole brain represent
500 mm; for all other images, 20 mm.
(B) Kaplan-Meier survival curve of NG2NPP mice tamoxifen-induced at 4–8 weeks and aged until symptomatic (n = 15 NG2NPP, 10 controls).
(C) Bar graph showing percentage of NG2NPP tumors classified as either WHO grade III (n = 5) or IV (n = 6) gliomas or classified asmalignant astrocytomas (n = 6)
or mixed differentiation gliomas (anaplastic oligoastrocytomas or glioblastoma with oligodendroglioma component [GBMO]; n = 5).
(D) Representative H&E staining of a histologically identifiable high-grade glioma in a symptomatic NG2NPP mutant mouse compared to a control mouse brain.
White box indicates the tumor region magnified in the right top image; right bottom image shows the corresponding region in control brain. Scale bars in left two
images represent 1 mm; for right two images, 200 mm.
(E) Representative H&E staining of grade IV tumors in NG2NPP mutant mice showing pseudopalisading necrosis (a), oligodendrocytic differentiation (b), cir-
cumscribed tumor with a clear boundary (c), and tumor with less-defined borders (d). Scale bars represent 200 mm.
(legend continued on next page)
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Table 1. Human Glioblastoma Subtype Gene Sets Enriched in
Ascl1 Type 1 versus Type 2 Tumors
Human GBM Molecular
Subtype Gene Sets (TCGA)




p Value q Value
Mesenchymal 0.55 1.80 0.000 0.000
Classical 0.36 1.16 0.154 0.310
Proneural 0.36 1.14 0.192 0.246
Neural 0.33 1.05 0.331 0.347
ES, enrichment score; FDR q value, false discovery rate q value; NES,
normalized enrichment score; NOM p value, nominal p value.type 1 tumors (Figures 6Ec, 6Ed, and 6G) and were preferentially
found in ventral rather than dorsal brain (Figures 6D and 6H).
We next examined NG2NPP glioma gene expression profiles
(Figures S4B and S4C). Similar to AscNP type 2 tumors, clus-
tering analysis of NG2NPP tumors with CNS cell type-specific
gene profiles showed best alignment to OPCs (Figure 6I). Gene
set enrichment analysis (GSEA; Subramanian et al., 2005)
comparing AscNP type 1 and type 2 tumors with NG2NPP tu-
mors also showed higher normalized enrichment scores (NES),
and hence, greater alignment of NG2NPP tumors with type 2
gene sets compared to those of type 1 (Tables S4 and S5).
Thus, Ascl1-creERTM model type 2 and NG2-creERTM model tu-
mors show greater relatedness, consistent with both tumors
sharing OPCs as a common cell of origin.
GSEA was next used to examine the relatedness of type 1 and
2 gliomas to molecular signatures of human glioblastoma (Ver-
haak et al., 2010). Differentially expressed genes from compari-
son of Ascl1 type 1 versus type 2 tumors were derived and
analyzed for enrichment of the TCGA human molecular subtype
gene sets (mesenchymal, classical, proneural, and neural) by
GSEA. The data indicate that type 1 tumors show higher enrich-
ment scores than type 2 for the mesenchymal subtype gene sets
(Table 1). These analyses are consistent with the notion that adult
CNS progenitor-driven tumors exhibit similar genetic signatures
as human high-grade gliomas and that these glioma variants
represent molecularly distinct tumors.
Molecular Separation of Murine Gliomas Based on Cell
of Origin
The Ascl1-creERTM transgene drives tumor suppressor recombi-
nation in adult SVZ/SGZ neural progenitors and in adult OPCs,
giving rise to both type 1 and type 2 gliomas, whereas the NG2-
creERTM transgene is confined to adult OPCs and only forms
type 2 gliomas. We turned to a third tamoxifen inducible trans-
gene, Nestin-creERT2, that recombines SVZ/SGZ neural stem
and progenitor cell populations, and shows properties similar
to type 1 tumors (Alcantara Llaguno et al., 2009; Chen et al.,
2009). GSEA of Nestin-creERT2 GBM (Nestin-creERT2;Nf1flox/+;(F) Immunohistochemistry indicating expression of different markers in NG2NPP
(G) Bar graph showing percentage of NG2NPP gliomas that exhibit lesions with
(H) Frequency of tumor locations in NG2NPP tumors.
(I) Clustering analysis of NG2NPP tumors with adult murine CNS cell types show
See also Figure S4 and Tables S4 and S5.
CTrp53flox/flox;Ptenflox/+; NesNPP) compared to type 2-specific
NG2NPP (NG2-creERTM;Nf1flox/+;Trp53flox/flox;Ptenflox/+) tumors
revealed clear separation when plotted by LLE dimension reduc-
tion analysis (Figure 7A).
We then examined the transcriptional profiles of the three
mouse models AscNP, NesNPP, and NG2NPP. We first deter-
mined the similarity of the three tumor suppressormousemodels
with those of human GBM, other human tumors of the CNS and
other organ systems with GSEA (Sweet-Cordero et al., 2005). As
shown in Table S6, the AscNP, NesNPP and NG2NPP mouse
models exhibit the highest enrichment scores for human GBM,
and not oligodendroglioma or other CNS or non-CNS tumors,
indicating that the mouse models show the highest molecular
similarity to human GBM.
We next analyzed published data comparing the gene expres-
sion signatures of SVZ-derived stem cells versus OPCs (Becker-
vordersandforth et al., 2010), and found 1,249 differentially
expressed genes from this dataset (Table S7). Unsupervised hi-
erarchical clustering analysis showed that NesNPP and type 1
AscNP gliomas cluster together and separately from type 2 gli-
omas derived from NG2NPP and AscNP models (Figure 7B).
The heatmap showing the top 310 differentially expressed genes
with the highestmedian absolute deviation (MAD> 0.7; Table S8)
not only demonstrate separation of type 1 from type 2 GBMs but
also show unique expression patterns for all tumor subgroups as
well as lineage-specific signatures for GBMs initiated from adult
CNS stem cells, adult CNS progenitors, and adult OPCs.
Taken together, these microarray profiling data corroborate
the model that at least two separable pools of glioma-initiating
progenitors are susceptible to transformation by loss of identical
human glioma-relevant tumor suppressorsNf1, Trp53, and Pten,
in the adult mouse brain (Figure 7C). In addition to differing
biological characteristics, the resultant GBMs conserve distin-
guishing molecular features reflecting their cells of origin. The
development of two different glioblastoma subtypes derived
from two different progenitor populations with the same initiating
mutations show that, in addition to signature mutations and
pathways, the cell of origin for tumor initiation can be an impor-
tant determinant of GBM phenotype. Such findings in human
GBM would have important implications for tumor molecular
classification and treatment measures.
DISCUSSION
Extensivemolecular profiling of GBMhas yielded an ever-refined
genomic landscape (Dunn et al., 2012). These studies have led to
a variety of criteria that stratify GBM into molecular subtypes
(Phillips et al., 2006; Verhaak et al., 2010). However, functional
experimental evidence that validates the existence of biologi-
cally different tumor subclasses lags behind.
The aim of the present study was to examine the tumorigenic
potential of adult CNS committed progenitors and transit-ampli-
fying cells to form GBM. The results demonstrate that, indeed,tumors. Scale bar represents 200 mm.
identifiable borders (n = 7 well-defined versus n = 4 diffuse).
ing.
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Figure 7. Molecular Separation of Mouse
Gliomas Based on Cell of Origin
(A) LLE dimension reduction analysis showing the
expression of 18,000+ genes probed bymicroarray
and projected in 3-dimensional space in NesNPP
and NG2NPP mouse models and their controls.
(B) Analysis of mouse model gene expression pro-
files based on cell of origin. Top images show
representative tumors derived from Ascl1-creERTM
(type 1 and 2 tumors shown), Nestin-creERT2, and
NG2-creERTM models. Unsupervised hierarchical
clustering analysis of AscNP, NesNPP, and
NG2NPP tumors using differentially expressed
genes from published data comparing SVZ neural
stem cells and OPCs (Beckervordersandforth et al.,
2010). Heatmap represents the gene expression
profile of the top 310 differentially expressed genes
with the highest median absolute deviation (MAD >
0.7) showing the molecular separation of the mouse
model tumorsbasedon the tumor-initiatingcell. Side
bars indicate lineage-specific signatures that high-
light distinct expression patterns by GBMs derived
from NSCs (NesNPP), progenitors (AscNP type 1
and 2), and OPCs (NG2NPP). Bottom bars empha-
size the common type 1 (NesNPPandAscNP type 1)
and type 2 (NG2NPP and AscNP type 2) tumors.
(C) Model of adult progenitor cell of origin of gli-
omas. Our studies are consistent with the presence
of at least two distinct lineages of GBM-initiating
progenitors in the adult mouse brain. GBMs show
overlapping histologic similarity but retain molecu-
lar differences arising from different cellular origins.
See also Tables S6–S8.adult CNS progenitor cells harboring the same glioma relevant
mutations as applied to stem cells, can give rise to GBM effi-
ciently. An unexpected result identified two pathologically similar
butmolecularly distinct GBM tumor types that arise from different
cells of origin that normally specify separate adult lineages.
Thus, despite limited self-renewal and restricted differen-
tiation potential, tumor suppressor deletion can initiate the
tumorigenic cascade in two types of adult CNS progenitors.
Similar to committed hematopoietic cells, the data indicate
that adult neural and oligodendrocyte progenitors are able to
overcome programmed limitations necessary to engender gli-
oma. In leukemias, oncogenes such as MLL have been shown
to confer properties of enhanced self-renewal (Huntly et al.,
2004), which allow transformed hematopoietic progenitors to
self-renew indefinitely and acquire additional mutations. We
observe early proliferation and differentiation defects in AscNP
mutants, suggesting that tumor suppressor loss likewise leads
to changes in intrinsic programming in transformedCNSprogen-
itor cells.
GBM affects adults with a median age of 64 years at time of
diagnosis (Stupp et al., 2005; Wen and Kesari, 2008). In light of
the known phenotypic differences between embryonic and adult
cells (Kriegstein and Alvarez-Buylla, 2009), it is unlikely that
spontaneous GBMs arise in embryonic cells, underscoring the
importance of adult-induced glioma mouse models. Unlike
studies that targeted cultured embryonic cells into mice that
developed tumors almost immediately (Ghazi et al., 2012), we
purposely used a variety of inducible transgenic mice that al-
lowed temporal control of gene ablation in adult brains.438 Cancer Cell 28, 429–440, October 12, 2015 ª2015 Elsevier Inc.The Ascl1-creERTM transgene promotes LoxP recombination
and GBM tumorigenesis in both adult neural and oligodendro-
cyte progenitors. However, two separable types of tumors
emerge in AscNP and AscNPP mutants, with type 1 GBMs
resembling the majority of gliomas found in the Nestin-creERT2
(Alcantara Llaguno et al., 2009) and hGFAP-Cre lines (Chen
et al., 2012a; Kwon et al., 2008; Zhu et al., 2005), and a second
subset of GBMs, designated as type 2. The dual specificity of
the Ascl1-creERTM transgene to both types of progenitors raised
the possibility that type 2 GBMs arose from adult OPCs. We
confirmed this hypothesis using the NG2NPP models.
The presence of type 1-like tumors in the neural stem cell-spe-
cific NesNPP models, which molecularly clustered with type 1
AscNP tumors, indicates that the Nestin-creERT2 models fate
into the same cells as Ascl1-creERTM adult neural progenitor
cells. This suggests that the progenitor stage might be a com-
mon endpoint for transformed CNS cells, similar to findings in
leukemia models (Cozzio et al., 2003). Retrospective analysis
of the hGFAP-Cre-driven glioma models revealed that these
mice also develop type 2 gliomas, which becamemost apparent
upon growth arrest of type 1 tumors through HSV-thymidine
kinase transgene-targeted killing of cancer stem cells (Chen
et al., 2012a).
OPCs have also been implicated as cells of origin for another
less frequent CNS malignancy, oligodendroglioma. Extensive
analyses show that type 2 GBMs are histologically, genetically,
and molecularly most similar to GBM and are entirely different
from oligodendroglioma, which do not associate with mutations
in NF1 or TP53 (Ohgaki and Kleihues, 2005).
Our study identifies adult OPCs as a source for only one type
of high-grade glioma, the type 2 GBM. Zong and colleagues
have induced gliomas by recombination of the Nf1 and Trp53
tumor suppressors in oligodendrocytic progenitors and found
tumors that appear to be found in the ventral brain (Galvao
et al., 2014; Liu et al., 2011). Taking the present results into
consideration, it is likely that Zong and colleagues are modeling
the type 2 gliomas described here.
Dramatic advances in genomic technology has permitted
molecular stratification of glioblastomas on the basis of gene
transcription, copy number, chromosomal integrity, mutation
spectrum, and related data (Li et al., 2012; Phillips et al., 2006;
Verhaak et al., 2010). These compelling classifications have pro-
vided momentum to the notion that driver mutations and their
molecular pathways define GBM subtypes. However, the clinical
implications of these genome-based classifications remain less
clear.
Our data point to a contrasting scenario in which identical
GBM relevant driver mutations and pathways can promote bio-
logically different tumor types based on the tumor cell of origin.
Type 1 and 2 GBMs arise in different adult progenitor lineages
and develop unique cell autonomous phenotypes, gene expres-
sion profiles, and natural history. Our mouse models suggest
that GBM development and prognosis may reflect not only the
sum of pathological features and the molecular driver genes,
but equally or more so, the cell of origin in which the mutations
arose. These observations are congruent with those of EWS-
ATF1-induced clear cell sarcoma mouse models reported by
the Capecchi group (Straessler et al., 2013). Thus, use of physi-
ologically relevant glioma mouse models to directly target
different brain cell populations using diverse mutations
frequently found in GBM may serve as complementary tools to-
ward a more refined classification of tumor subtypes that takes
the cell of origin and functional analysis into consideration
together with human clinical and genomic data.EXPERIMENTAL PROCEDURES
Additional details are available in the Supplemental Experimental Procedures.Mouse Experiments
All mouse experiments were approved and performed according to the guide-
lines of the Institutional Animal Care and Use Committee of the University of
Texas Southwestern Medical Center at Dallas. Mice with the Ascl1-creERTM
(Kim et al., 2007),NG2-creERTM (Zhu et al., 2011), orNestin-creERT2 (Alcantara
Llaguno et al., 2009; Chen et al., 2009) transgenes were crossed with condi-
tional or null Nf1, Trp53, and/or Pten alleles and the R26-stop-lacZ, R26-
stop-YFP, or R26-stop-TdTomato reporters. Tumor suppressor floxed mice
containing the Cre transgenes were administered with tamoxifen (Sigma) or
vehicle by oral gavage at adult ages (4–8 weeks of age) and aged until symp-
tomatic or at indicated time points.Histology and Tumor Analysis
Brain sections were independently examined by S.A.L., Z.W., J.C., D.K.B.,
J.M.R., and K.J.H., the latter three being certified neuropathologists, and tu-
mor diagnosis was determined based on the WHO criteria (Louis et al.,
2007). PCR genotyping and western blot analysis using tumor and non-tumor
tissues and/or cells, were performed as previously described (Kwon et al.,
2008). Paraffin or vibratome brain sections were analyzed with H&E and
X-gal staining, as well as fluorescence and horseradish peroxidase-based im-
munostaining, as previously described (Alcantara Llaguno et al., 2009).CTissue Culture and Transplantations
Primary tumor tissues were freshly dissected from symptomatic mutant mice
and SVZ from age-matched mice were used as controls. Harvested tissues
were minced into single cell suspension and grown as neurospheres. Self-
renewal, differentiation, and ATP assays were performed as previously
described (Alcantara Llaguno et al., 2009).
For transplantation experiments, 4-week-old female nu/numice were anes-
thetized and directly injected with 2 3 105 tumor cells into the dorsal striatum
(coordinates: 0 AP, 1.4 ML, 2.3 DV with respect to the bregma). Mice were
aged until symptomatic.
Gene Expression Profile Analysis
Primary tumor tissue and respective control brains were harvested from symp-
tomatic AscNP, NG2NPP, and NesNPP mutants and control mice. Total RNA
extracted from samples was submitted to the UT Southwestern Microarray
Core for analysis using IlluminaWG-6 V2 BeadChips. Statistical analysis of mi-
croarray data is described in greater detail in the Supplemental Experimental
Procedures.
ACCESSION NUMBERS
The accession number for the Ascl1-creERTM model microarray data
reported in this paper is GEO: GSE57036. The accession number for the
Nestin-creERT2 and NG2-creERTM model microarray data reported in this pa-
per is GEO: GSE57038.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and eight tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccell.2015.09.007.
AUTHOR CONTRIBUTIONS
S.R.A.L., Z.W., D.S., and L.F.P. designed research. S.R.A.L, Z.W., J.C.,
and J.X. performed experiments. S.R.A.L., Z.W., D.S., J.C., D.K.B.,
J.M.R., K.J.H., J.E.J., and L.F.P. analyzed data. E.K., J.E.J., J.M.R., and
K.J.H. contributed new reagents/material. S.R.A.L. and L.F.P. wrote the
manuscript.
ACKNOWLEDGMENTS
The authors thank members of the L.F.P. lab for helpful suggestions and dis-
cussion. NG2-creERTM mice were acquired from Dr. Akiko Nishiyama. This
work was supported in part by a Children’s Tumor Foundation Young Investi-
gator Award and NIH T32 Postdoctoral Trainee support (2T32CA124334-06;
PI: Jerry Shay) to S.R.A.L. L.F.P. is an American Cancer Society Research Pro-
fessor and recipient of NIH R01 grant CA131313-01A1 and Cancer Prevention
and Research Institute of Texas Grant RP100782.
Received: May 5, 2014
Revised: July 8, 2015
Accepted: September 16, 2015
Published: October 12, 2015
REFERENCES
Alcantara Llaguno, S., Chen, J., Kwon, C.H., Jackson, E.L., Li, Y., Burns, D.K.,
Alvarez-Buylla, A., and Parada, L.F. (2009). Malignant astrocytomas originate
from neural stem/progenitor cells in a somatic tumor suppressor mouse
model. Cancer Cell 15, 45–56.
Alvarez-Buylla, A., and Lim, D.A. (2004). For the long run: maintaining germinal
niches in the adult brain. Neuron 41, 683–686.
Beckervordersandforth, R., Tripathi, P., Ninkovic, J., Bayam, E., Lepier, A.,
Stempfhuber, B., Kirchhoff, F., Hirrlinger, J., Haslinger, A., Lie, D.C., et al.
(2010). In vivo fate mapping and expression analysis reveals molecularancer Cell 28, 429–440, October 12, 2015 ª2015 Elsevier Inc. 439
hallmarks of prospectively isolated adult neural stem cells. Cell Stem Cell 7,
744–758.
Cahoy, J.D., Emery, B., Kaushal, A., Foo, L.C., Zamanian, J.L.,
Christopherson, K.S., Xing, Y., Lubischer, J.L., Krieg, P.A., Krupenko, S.A.,
et al. (2008). A transcriptome database for astrocytes, neurons, and oligoden-
drocytes: a new resource for understanding brain development and function.
J. Neurosci. 28, 264–278.
Cancer Genome Atlas Research Network (2008). Comprehensive genomic
characterization defines human glioblastoma genes and core pathways.
Nature 455, 1061–1068.
Chen, J., Kwon, C.H., Lin, L., Li, Y., and Parada, L.F. (2009). Inducible site-spe-
cific recombination in neural stem/progenitor cells. Genesis 47, 122–131.
Chen, J., Li, Y., Yu, T.S., McKay, R.M., Burns, D.K., Kernie, S.G., and Parada,
L.F. (2012a). A restricted cell population propagates glioblastoma growth after
chemotherapy. Nature 488, 522–526.
Chen, J., McKay, R.M., and Parada, L.F. (2012b). Malignant glioma: lessons
from genomics, mouse models, and stem cells. Cell 149, 36–47.
Cozzio,A.,Passegue´,E.,Ayton,P.M.,Karsunky,H.,Cleary,M.L., andWeissman,
I.L. (2003). Similar MLL-associated leukemias arising from self-renewing stem
cells and short-lived myeloid progenitors. Genes Dev. 17, 3029–3035.
Doetsch, F., Caille´, I., Lim, D.A., Garcı´a-Verdugo, J.M., and Alvarez-Buylla, A.
(1999). Subventricular zone astrocytes are neural stem cells in the adult
mammalian brain. Cell 97, 703–716.
Dunn, G.P., Rinne, M.L., Wykosky, J., Genovese, G., Quayle, S.N., Dunn, I.F.,
Agarwalla, P.K., Chheda, M.G., Campos, B., Wang, A., et al. (2012). Emerging
insights into the molecular and cellular basis of glioblastoma. Genes Dev. 26,
756–784.
Friedmann-Morvinski,D.,Bushong,E.A., Ke,E., Soda,Y.,Marumoto, T., Singer,
O., Ellisman, M.H., and Verma, I.M. (2012). Dedifferentiation of neurons and as-
trocytes by oncogenes can induce gliomas in mice. Science 338, 1080–1084.
Galvao, R.P., Kasina, A., McNeill, R.S., Harbin, J.E., Foreman, O., Verhaak,
R.G., Nishiyama, A., Miller, C.R., and Zong, H. (2014). Transformation of quies-
cent adult oligodendrocyte precursor cells into malignant glioma through a
multistep reactivation process. Proc. Natl. Acad. Sci. USA 111, E4214–E4223.
Ghazi, S.O., Stark, M., Zhao, Z., Mobley, B.C., Munden, A., Hover, L., and
Abel, T.W. (2012). Cell of origin determines tumor phenotype in an oncogenic
Ras/p53 knockout transgenic model of high-grade glioma. J. Neuropathol.
Exp. Neurol. 71, 729–740.
Huntly, B.J., Shigematsu, H., Deguchi, K., Lee, B.H., Mizuno, S., Duclos, N.,
Rowan, R., Amaral, S., Curley, D., Williams, I.R., et al. (2004). MOZ-TIF2, but
not BCR-ABL, confers properties of leukemic stem cells to committed murine
hematopoietic progenitors. Cancer Cell 6, 587–596.
Jacques, T.S., Swales, A., Brzozowski, M.J., Henriquez, N.V., Linehan, J.M.,
Mirzadeh, Z., O’ Malley, C., Naumann, H., Alvarez-Buylla, A., and Brandner,
S. (2010). Combinations of genetic mutations in the adult neural stem cell
compartment determine brain tumour phenotypes. EMBO J. 29, 222–235.
Kim, E.J., Leung, C.T., Reed, R.R., and Johnson, J.E. (2007). In vivo analysis of
Ascl1 defined progenitors reveals distinct developmental dynamics during
adult neurogenesis and gliogenesis. J. Neurosci. 27, 12764–12774.
Kim, E.J., Battiste, J., Nakagawa, Y., and Johnson, J.E. (2008). Ascl1 (Mash1)
lineage cells contribute to discrete cell populations in CNS architecture. Mol.
Cell. Neurosci. 38, 595–606.
Kriegstein, A., and Alvarez-Buylla, A. (2009). The glial nature of embryonic and
adult neural stem cells. Annu. Rev. Neurosci. 32, 149–184.
Krivtsov, A.V., Twomey, D., Feng, Z., Stubbs, M.C., Wang, Y., Faber, J.,
Levine, J.E., Wang, J., Hahn, W.C., Gilliland, D.G., et al. (2006).
Transformation from committed progenitor to leukaemia stem cell initiated
by MLL-AF9. Nature 442, 818–822.
Kwon, C.H., Zhao, D., Chen, J., Alcantara, S., Li, Y., Burns, D.K., Mason, R.P.,
Lee, E.Y., Wu, H., and Parada, L.F. (2008). Pten haploinsufficiency accelerates
formation of high-grade astrocytomas. Cancer Res. 68, 3286–3294.
Li, B., Senbabaoglu, Y., Peng, W., Yang, M.L., Xu, J., and Li, J.Z. (2012).
Genomic estimates of aneuploid content in glioblastoma multiforme and
improved classification. Clin. Cancer Res. 18, 5595–5605.440 Cancer Cell 28, 429–440, October 12, 2015 ª2015 Elsevier Inc.Lillien, L. (1998). Neural progenitors and stem cells: mechanisms of progenitor
heterogeneity. Curr. Opin. Neurobiol. 8, 37–44.
Liu, C., Sage, J.C., Miller, M.R., Verhaak, R.G., Hippenmeyer, S., Vogel, H.,
Foreman, O., Bronson, R.T., Nishiyama, A., Luo, L., and Zong, H. (2011).
Mosaic analysis with double markers reveals tumor cell of origin in glioma.
Cell 146, 209–221.
Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Burger, P.C., Jouvet,
A., Scheithauer, B.W., and Kleihues, P. (2007). The 2007 WHO classification
of tumours of the central nervous system. Acta Neuropathol. 114, 97–109.
Mich, J.K., Signer, R.A., Nakada, D., Pineda, A., Burgess, R.J., Vue, T.Y.,
Johnson, J.E., andMorrison, S.J. (2014). Prospective identification of function-
ally distinct stem cells and neurosphere-initiating cells in adult mouse fore-
brain. eLife 3, e02669.
Nishiyama, A., Komitova, M., Suzuki, R., and Zhu, X. (2009). Polydendrocytes
(NG2 cells): multifunctional cells with lineage plasticity. Nat. Rev. Neurosci. 10,
9–22.
Ohgaki, H., and Kleihues, P. (2005). Population-based studies on incidence,
survival rates, and genetic alterations in astrocytic and oligodendroglial gli-
omas. J. Neuropathol. Exp. Neurol. 64, 479–489.
Phillips, H.S., Kharbanda, S., Chen, R., Forrest, W.F., Soriano, R.H., Wu, T.D.,
Misra, A., Nigro, J.M., Colman, H., Soroceanu, L., et al. (2006). Molecular sub-
classes of high-grade glioma predict prognosis, delineate a pattern of disease
progression, and resemble stages in neurogenesis. Cancer Cell 9, 157–173.
Reya, T., Morrison, S.J., Clarke, M.F., and Weissman, I.L. (2001). Stem cells,
cancer, and cancer stem cells. Nature 414, 105–111.
Sanai, N., Alvarez-Buylla, A., and Berger, M.S. (2005). Neural stem cells and
the origin of gliomas. N. Engl. J. Med. 353, 811–822.
Sell, S. (2010). On the stem cell origin of cancer. Am. J. Pathol. 176, 2584–2494.
Straessler, K.M., Jones, K.B., Hu, H., Jin, H., van de Rijn, M., and Capecchi,
M.R. (2013). Modeling clear cell sarcomagenesis in the mouse: cell of origin
differentiation state impacts tumor characteristics. Cancer Cell 23, 215–227.
Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn,
M.J., Belanger, K., Brandes, A.A., Marosi, C., Bogdahn, U., et al.; European
Organisation for Research and Treatment of Cancer Brain Tumor and
Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials
Group (2005). Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N. Engl. J. Med. 352, 987–996.
Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L.,
Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and
Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based
approach for interpreting genome-wide expression profiles. Proc. Natl.
Acad. Sci. USA 102, 15545–15550.
Sweet-Cordero, A., Mukherjee, S., Subramanian, A., You, H., Roix, J.J., Ladd-
Acosta, C., Mesirov, J., Golub, T.R., and Jacks, T. (2005). An oncogenic
KRAS2 expression signature identified by cross-species gene-expression
analysis. Nat. Genet. 37, 48–55.
Verhaak, R.G., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D.,
Miller, C.R., Ding, L., Golub, T., Mesirov, J.P., et al.; Cancer Genome Atlas
Research Network (2010). Integrated genomic analysis identifies clinically rele-
vant subtypes of glioblastoma characterized by abnormalities in PDGFRA,
IDH1, EGFR, and NF1. Cancer Cell 17, 98–110.
Visvader, J.E. (2011). Cells of origin in cancer. Nature 469, 314–322.
Wen, P.Y., and Kesari, S. (2008). Malignant gliomas in adults. N. Engl. J. Med.
359, 492–507.
Zhao, C., Deng, W., and Gage, F.H. (2008). Mechanisms and functional impli-
cations of adult neurogenesis. Cell 132, 645–660.
Zhu, Y., Guignard, F., Zhao, D., Liu, L., Burns, D.K., Mason, R.P., Messing, A.,
and Parada, L.F. (2005). Early inactivation of p53 tumor suppressor gene coop-
erating with NF1 loss induces malignant astrocytoma. Cancer Cell 8, 119–130.
Zhu, X., Hill, R.A., Dietrich, D., Komitova, M., Suzuki, R., and Nishiyama, A.
(2011). Age-dependent fate and lineage restriction of single NG2 cells.
Development 138, 745–753.
